From the perspective of the sector, we believe that pharmaceutical stocks are rich in "themes" and have always been the hot spot of capital chasing in the bull market. Recently, the pharmaceutical sector has been stimulated by the continuous daily limit, and under the huge price comparison effect, it has launched an overall upward trend, such as Southwest Pharmaceutical Nanjing Pharmaceutical. On the other hand, the pharmaceutical industry has been strongly supported by policies, and medical reform is still the most important theme in the future. The preliminary plan of overall medical reform may be introduced, pharmacy trusteeship may make a breakthrough, and centralized bidding and procurement of drugs in various places will be gradually rolled out. Under the background of medical reform, it brings unprecedented development opportunities to listed companies in related pharmaceutical industries.
In the secondary market, when the overall plan of the new round of medical and health system reform is being improved, the basic medical insurance for urban residents, as an important part of it, takes the lead. In the secondary market, the pharmaceutical sector is ready to go, and a "storm" of rising pharmaceutical sector swept the Shanghai and Shenzhen markets.
Jiangsu Wuzhong (600200): As a low-priced pharmaceutical potential stock that has been seriously neglected by the market, the recent moderate enlargement of the bottom trading volume of this stock indicates the intervention of new funds. As can be seen from the company's interim report in 2007, the company's pharmaceutical industry income has been enough to compete with the traditional clothing industry, and both the scale of operation and the gross profit margin have remained at a high level. At the same time, the company has jointly developed a series of new drugs to treat tumor angiogenesis inhibitors with Nanjing College of the Second Military Medical University of China People's Liberation Army and * *, which has a good development prospect. Its leading product, recombinant human granulocyte colony stimulating factor, is a national second-class new drug. It adopts the patented new technology of recombinant protein extraction and purification, which has high absorption rate, high purity, high activity and good market condition, laying a good foundation for the company's sustainable development.
In the secondary market, Wuzhong, Jiangsu (600200): The stock has been active, and there is often a sudden daily limit. Recently, the stock has obviously formed a consolidation trend at the bottom, and the moderate amplification of trading volume shows the involvement of incremental funds. With the buying signals of various technical indicators, the stock is expected to regain its upward trend in the short term.